Arquitos returned 64.8% net in Q2 2026 driven by strong performance in Liquidia and Abivax. Read the full letter for more details.
ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...
ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...
Abivax is advancing obefazimod for ulcerative colitis and Crohn’s, with recent safety concerns now largely addressed. Read more on ABVX stock here.
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Abivax (ABVX) has an average rating of buy and mean price target of $164.20, according to analysts p
Abivax (ABVX) said Monday Fabio Cataldi will be leaving the company in the fourth quarter of 2026, a
Companies Reporting Before The Bell • Ennis (NYSE:EBF) is expected to report earnings for its second quarter. Companies Reporting After The Bell • Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 per
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Abivax (ABVX) has an average rating of buy and mean price target of $162.06, according to analysts p
Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis...
This is the newest page. Registered accounts read further back.